First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Resistance, Neoplasm
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

abstract

  • The recommended dose of CPX-351 for phase II study is 101 units/m(2). Further exploration of efficacy and safety is ongoing in phase II trials in newly diagnosed and first-relapse patients with AML.

publication date

  • March 10, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4520927

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.30.5961

PubMed ID

  • 21282541

Additional Document Info

start page

  • 979

end page

  • 85

volume

  • 29

number

  • 8